LILLY (ELI) & COMPANY: Dr Marschall S Runge Elected to Lilly Board of Directors

LILLY (ELI) & COMPANY: Dr Marschall S Runge Elected to Lilly Board of Directors
Date: August 28, 2013                                                           
For Release: Immediately 
Refer to: (317) 433-9899 - Edward Sagebiel 
      Dr. Marschall S. Runge Elected to Lilly Board of Directors            
The Board of Directors of Eli Lilly and Company (NYSE:LLY) has elected
Marschall S. Runge, M.D., Ph.D., as a new member, effective September 1, 2013.
Dr. Runge, 59, is the Executive Dean for the School of Medicine at the
University of North Carolina at Chapel Hill (UNC). As a member of Lilly's
board, Dr. Runge will serve on the Science and Technology Committee and the
Public Policy and Compliance Committee. 
"I am very pleased to welcome Marschall Runge to the Lilly board," said John
Lechleiter, Ph.D., Lilly chairman, president and chief executive officer. "Dr.
Runge brings to the Lilly board a broad background in health care, with
extensive experience as a practicing physician, clinical researcher, and dean
of a major academic medical institution. His appreciation of the importance of
scientific research, coupled with his first-hand experience in patient care,
will help Lilly deliver on its commitment to discover and develop innovative
medicines that make a difference for patients in need." 
In his role as Executive Dean for the UNC School of Medicine, Dr. Runge
provides overall academic and clinical leadership for the School of Medicine
and the UNC Health Care System. In addition to being the Chair of the
Department of Medicine, Dr. Runge is also Principal Investigator and Director
of the North Carolina Translational and Clinical Sciences (NC TraCS) Institute
at UNC-Chapel Hill, where he has financial, human resource and strategic
oversight responsibilities for the program. The NC TraCS Institute is one of 60
medical research institutions working together as part of a national consortium
to improve the way biomedical research is conducted across the country and to
reduce the time it takes for laboratory discoveries to become new treatments
for patients. 
An honors graduate of Vanderbilt University with a B.A. in Biology and a Ph.D.
in molecular biology, Dr. Runge earned his M.D. from the Johns Hopkins School
of Medicine, where he was an intern and resident in internal medicine. He then
completed a cardiology fellowship at Harvard's Massachusetts General Hospital
and was a faculty member there prior to moving to Emory University as an
Associate Professor of Medicine in 1989. Before joining the UNC faculty in
2000, Dr. Runge held the John Sealy Distinguished Centennial Chair in Internal
Medicine and was Director of the Division of Cardiology and the Sealy Center
for Molecular Cardiology at the University of Texas Medical Branch at
Galveston. 
In addition to serving as a member of the Experimental Cardiovascular Sciences
Study Section of the National Institutes of Health, Dr. Runge also has
published over 150 peer-reviewed manuscripts and is a renowned leader in
vascular biology. 
About Lilly 
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -
through medicines and information - for some of the world's most urgent medical
needs. Additional information about Lilly is available at www.lilly.com. C-LLY 
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A.
www.lilly.com 
END 
-0- Aug/28/2013 13:20 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.